Tvardi Therapeutics (LTS:0HTC) EBIT: £-21.89 Mil (TTM As of Mar. 2026)

What is Tvardi Therapeutics EBIT?

Tvardi Therapeutics LTS:0HTC 12 EBIT is £-21.89 Mil as of Mar. 2026. GuruFocus rates LTS:0HTC with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Tvardi Therapeutics's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was £-5.29 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was £-21.89 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Tvardi Therapeutics's annualized ROC % for the quarter that ended in Mar. 2026 was -1,719.67%. Tvardi Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -15,552.94%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield.

Tvardi Therapeutics (LTS:0HTC) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Tvardi Therapeutics's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

	ROC % (Q: Mar. 2026 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2025 )	+	Invested Capital (Q: Mar. 2026 ))	/ count )
=	-21.152 * ( 1 - 0% )	/	( (1.455	+	1.005)	/ 2 )
=	-21.152	/	1.23
=	-1,719.67 %

where

	Invested Capital		(Q: Dec. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	23.959	-	7.193	-	( 23.016	-	max(0, 8.248	-	23.559	+	23.016	))
=	1.455

	Invested Capital		(Q: Mar. 2026 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	19.363	-	7.807	-	( 18.736	-	max(0, 8.444	-	18.995	+	18.736	))
=	1.005

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Tvardi Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2026 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2025		Q: Mar. 2026
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-21.152	/	( ( (0.146 + max(-7.618, 0))	+	(0.126 + max(-8.095, 0)) )	/	2 )
=	-21.152	/	( ( 0.146	+	0.126 )	/	2 )
=	-21.152	/	0.136
=	-15,552.94 %

where Working Capital is:

	Working Capital		(Q: Dec. 2025 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.543)	-	(7.193	+	0	+	0.968)
=	-7.618

	Working Capital		(Q: Mar. 2026 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.259)	-	(7.807	+	0	+	0.547)
=	-8.095

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Tvardi Therapeutics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2026 )
	=	-21.885	/	0.000
	=	%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tvardi Therapeutics EBIT Related Terms

Tvardi Therapeutics EBIT Historical Data

* Premium members only.

The historical data trend for Tvardi Therapeutics's EBIT can be seen below:

Tvardi Therapeutics EBIT Chart

Tvardi Therapeutics Annual Data

Trend

Dec22

Dec23

Dec24

Dec25

EBIT

-16.86

-13.70

-22.23

-19.98

Tvardi Therapeutics Quarterly Data
	Dec22	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
EBIT	Get a 7-Day Free Trial						-3.37	-6.54	-4.39	-5.67	-5.29

LTS:0HTC vs PLRZ, BOLD, APLM: EBIT Comparison

For the Biotechnology subindustry, Tvardi Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tvardi Therapeutics EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tvardi Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Tvardi Therapeutics's EV-to-EBIT falls into.

Save Embed

Tvardi Therapeutics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was £-21.89 Mil.

Frequently Asked Questions Learn more about EBIT →

What does a EBIT of £-21.89 Mil mean?

Tvardi Therapeutics (LTS:0HTC) has a EBIT of £-21.89 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Tvardi Therapeutics.

Is Tvardi Therapeutics' EBIT too high?

Tvardi Therapeutics' current EBIT is £-21.89 Mil. Overall, Tvardi Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.

How does Tvardi Therapeutics' EBIT compare to PLRZ and BOLD?

Tvardi Therapeutics' EBIT of £-21.89 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBIT for a Biotechnology company?

A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBIT mean?

A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Tvardi Therapeutics. Tvardi Therapeutics's current EBIT is £-21.89 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Tvardi Therapeutics stock overvalued right now?

Tvardi Therapeutics (LTS:0HTC) has a current EBIT of £-21.89 Mil. The current EBIT is £-21.89 Mil. Tvardi Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBIT calculated?

EBIT is calculated from a company's financial statements. For Tvardi Therapeutics (LTS:0HTC), the current EBIT is £-21.89 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Tvardi Therapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies PLRZ BOLD APLM TVGN DARE LSTA NRSN SNTI DYAI LITS VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges TVRD:USA 69C:Germany

Address 3 Sugar Creek Center boulevard, Suite 525, Sugar Land, TX, USA, 77478

Website https://www.tvarditherapeutics.com

Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.